Boston Scientific Corp

Boston Scientific tops Q1 earnings, beating EPS estimates but cuts 2026 sales guidance amid supply‑chain uncertainty—stock surges yet faces legal deadlines.

Boston Scientific shares hit a $61.86 close as investors face a May 4, 2026 litigation deadline—earnings guidance shows upside while institutional selling raises caution.

Boston Scientific’s CHAMPION‑AF trial hits all endpoints, boosting its $93B market cap. See how institutional trades, SEC filings, and device launches shape its growth.

Boston Scientific’s WATCHMAN FLX and EKOS trials confirm breakthrough safety, boosting market confidence amid active trading and a pending class‑action lawsuit.

Boston Scientific (BSX) sees bullish analyst coverage, institutional buys, and steady but declining prices—insightful for investors targeting health‑care equipment growth.

Boston Scientific Corp. has reported a strong third-quarter performance, exceeding analyst expectations and boosting its annual profit forecast, driven by surging demand for its heart-device portfolio.

Boston Scientific Corp has reported a 22.8% increase in net sales to $5.061 billion, exceeding expectations and setting a new benchmark for the company’s financial performance.

Boston Scientific Corp reported strong Q1 2025 earnings, exceeding market expectations and prompting an upgrade in its full-year guidance, despite facing external challenges.